BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20124408)

  • 1. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
    Demma M; Maxwell E; Ramos R; Liang L; Li C; Hesk D; Rossman R; Mallams A; Doll R; Liu M; Seidel-Dugan C; Bishop WR; Dasmahapatra B
    J Biol Chem; 2010 Apr; 285(14):10198-212. PubMed ID: 20124408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A regulatory loop composed of RAP80-HDM2-p53 provides RAP80-enhanced p53 degradation by HDM2 in response to DNA damage.
    Yan J; Menendez D; Yang XP; Resnick MA; Jetten AM
    J Biol Chem; 2009 Jul; 284(29):19280-9. PubMed ID: 19433585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
    Phillips A; Teunisse A; Lam S; Lodder K; Darley M; Emaduddin M; Wolf A; Richter J; de Lange J; Verlaan-de Vries M; Lenos K; Böhnke A; Bartel F; Blaydes JP; Jochemsen AG
    J Biol Chem; 2010 Sep; 285(38):29111-27. PubMed ID: 20659896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells.
    Ding L; Zhang Z; Zhao C; Chen L; Chen Z; Zhang J; Liu Y; Nie Y; He Y; Liao K; Zhang X
    J Exp Clin Cancer Res; 2021 Aug; 40(1):245. PubMed ID: 34362424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination.
    Nie L; Sasaki M; Maki CG
    J Biol Chem; 2007 May; 282(19):14616-25. PubMed ID: 17371868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific domains of nucleolin interact with Hdm2 and antagonize Hdm2-mediated p53 ubiquitination.
    Bhatt P; d'Avout C; Kane NS; Borowiec JA; Saxena A
    FEBS J; 2012 Feb; 279(3):370-83. PubMed ID: 22103682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
    Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
    Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
    Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
    Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells.
    Dai F; Chen Y; Song Y; Huang L; Zhai D; Dong Y; Lai L; Zhang T; Li D; Pang X; Liu M; Yi Z
    PLoS One; 2012; 7(12):e52162. PubMed ID: 23300602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
    Yang L; Song T; Cheng Q; Chen L; Chen J
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
    Heminger K; Markey M; Mpagi M; Berberich SJ
    Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDM2 regulation by AURKA promotes cell survival in gastric cancer.
    Sehdev V; Katsha A; Arras J; Peng D; Soutto M; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
    Clin Cancer Res; 2014 Jan; 20(1):76-86. PubMed ID: 24240108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
    Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
    Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of nutlin-resistant HDM2 mutants by stapled peptides.
    Wei SJ; Joseph T; Chee S; Li L; Yurlova L; Zolghadr K; Brown C; Lane D; Verma C; Ghadessy F
    PLoS One; 2013; 8(11):e81068. PubMed ID: 24278380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-encoded EBNA-5 forms trimolecular protein complexes with MDM2 and p53 and inhibits the transactivating function of p53.
    Kashuba E; Yurchenko M; Yenamandra SP; Snopok B; Szekely L; Bercovich B; Ciechanover A; Klein G
    Int J Cancer; 2011 Feb; 128(4):817-25. PubMed ID: 20473904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor activity of vitamin C via p53 in cancer cells.
    Kim J; Lee SD; Chang B; Jin DH; Jung SI; Park MY; Han Y; Yang Y; Il Kim K; Lim JS; Kang YS; Lee MS
    Free Radic Biol Med; 2012 Oct; 53(8):1607-15. PubMed ID: 22892142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro selection of mutant HDM2 resistant to Nutlin inhibition.
    Wei SJ; Joseph T; Sim AY; Yurlova L; Zolghadr K; Lane D; Verma C; Ghadessy F
    PLoS One; 2013; 8(4):e62564. PubMed ID: 23653682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.